Yanuar Andre, Agustina Hasrayati, Antarianto Radiana Dhewayani, Hidajat Nucki Nursjamsi, Mahyuddin Andi Isra, Dilogo Ismail Hadisoebroto, Budhiparama Nicolaas Cyrillus, Atik Nur
Doctoral Program, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Department of Orthopaedic and Traumatology, Santo Borromeus Hospital, Bandung 40132, Indonesia.
Biomolecules. 2025 Mar 10;15(3):396. doi: 10.3390/biom15030396.
In this research, we want to find out whether extracellular vesicles (EVs) from adipose-derived mesenchymal stem cells (MSCs) can improve ligament-bone integration after primary Anterior Cruciate Ligament (ACL) repair by performing immunological and biomechanical tests.
All of the rabbits underwent ACL resection at the proximal attachment to the femur bone, and then were divided into four groups. We performed an ELISA examination from the tissue at the bone-ligament interface of iNOS, CD206, MMP-3, and TIMP-1 to evaluate their levels at the inflammatory stage at the end of the first week. Immunoexpression of type I and III collagen and failure load biomechanical tests were performed at the end of the sixth week.
The group that underwent ACL repair with EVs augmentation had significantly higher levels of CD206, significantly lower MMP-3 levels, and significantly higher TIMP-1 levels in the first week. The iNOS levels in the group that underwent ACL repair with EVs augmentation were significantly different compared to the control group that did not receive any. The number of type I collagen fibers and the failure load levels in the group that underwent ACL repair with EVs augmentation were significantly higher.
EVs from adipose-derived MSCs can improve the outcome of primary ACL repair in rabbits by regulating the inflammatory process during the healing period.
在本研究中,我们希望通过进行免疫学和生物力学测试,来探究脂肪来源间充质干细胞(MSCs)分泌的细胞外囊泡(EVs)能否在初次前交叉韧带(ACL)修复后改善韧带-骨整合。
所有兔子均在股骨近端附着处进行ACL切除,然后分为四组。我们对骨-韧带界面组织进行了ELISA检测,以评估一氧化氮合酶(iNOS)、CD206、基质金属蛋白酶-3(MMP-3)和金属蛋白酶组织抑制因子-1(TIMP-1)在第一周结束时炎症阶段的水平。在第六周结束时进行了I型和III型胶原蛋白的免疫表达以及失效载荷生物力学测试。
在第一周,接受EVs增强ACL修复的组中,CD206水平显著更高,MMP-3水平显著更低,TIMP-1水平显著更高。接受EVs增强ACL修复的组中的iNOS水平与未接受任何处理的对照组相比有显著差异。接受EVs增强ACL修复的组中I型胶原纤维数量和失效载荷水平显著更高。
脂肪来源MSCs的EVs可通过在愈合期调节炎症过程来改善兔子初次ACL修复的结果。